Revisión narrativa de la terapia inhalatoria en la EPOC

Bibliographic References

• M. Miravitlles, M. Calle, J. Molina, P. Almagro, J.T. Gómez, J.A. Trigueros, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD Arch Bronconeumol (Engl Ed). (2021), 10.1016/j.arbres.2021.03.005 View PDFGoogle Scholar
• M. Reza Maleki-Yazdi, M. Molimard, D.L. Keininger, J.B. Gruenberger, J. Carrasco, C. Pitotti, et al. Cost effectiveness of the long-acting β2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: Analyses conducted for Canada, France, Italy, and Portugal Appl Health Econ Health Policy., 14 (2016), pp. 579-594 View PDFCrossRefView Record in ScopusGoogle Scholar
• J.A. Wedzicha, D. Banerji, K.R. Chapman, J. Vestbo, N. Roche, R.T. Ayers, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD N Engl J Med., 374 (2016), pp. 2222-2234 View PDFCrossRefView Record in ScopusGoogle Scholar
• N. Horita, N. Miyazawa, K. Tomaru, M. Inoue, T. Kaneko Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis Respirology., 20 (2015), pp. 1153-1159 View PDFCrossRefView Record in ScopusGoogle Scholar
• N. Zhong, C. Wang, X. Zhou, N. Zhang, M. Humphries, L. Wang, et al. LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD Int J Chron Obstruct Pulmon Dis., 10 (2015), pp. 1015-1026 View Record in ScopusGoogle Scholar
• D. Price, D. Keininger, M. Costa-Scharplatz, K. Mezzi, M. Dimova, Y. Asukai Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting Respir Med., 108 (2014), pp. 1786-1793 ArticleDownload PDFView Record in ScopusGoogle Scholar
• J.C. Samp, M.J. Joo, G.T. Schumock, G.S. Calip, A.S. Pickard, T.A. Lee Comparative effectiveness of long-acting beta2-agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease Pharmacotherapy., 37 (2017), pp. 447-455, 10.1002/phar.1913 View PDFView Record in ScopusGoogle Scholar
• J.A. Wedzicha, N. Zhong, M. Ichinose, M. Humphries, R. Fogel, C. Thach, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: Results from the FLAME study Int J Chron Obstruct Pulmon Dis., 12 (2017), pp. 339-349, 10.2147/COPD.S125058 View PDFView Record in ScopusGoogle Scholar
• C. Vogelmeier, N. Zhong, M.J. Humphries, K. Mezzi, R. Fogel, G. Bader, et al. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis Int J Chron Obstruct Pulmon Dis., 11 (2016), pp. 3189-3197, 10.2147/COPD.S116786 View PDFView Record in ScopusGoogle Scholar
• N. Zhong, C. Wang, X. Zhou, N. Zhang, M. Humphries, L. Wang, et al. Efficacy and safety of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone in Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: The Chinese cohort from the LANTERN study COPD., 13 (2016), pp. 686-692 View PDFCrossRefView Record in ScopusGoogle Scholar
• N. Horita, A. Goto, Y. Shibata, E. Ota, K. Nakashima, K. Nagai, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD) Cochrane Database Syst Rev, Issue2 (2017), 10.1002/14651858.CD012066.pub2 CD012066 View PDFGoogle Scholar
• J.A. Wedzicha, D. Singh, I. Tsiligianni, C. Jenkins, S. Fucile, R. Fogel, et al. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: A post-hoc analysis in the FLAME study Respir Res., 20 (2019), p. 4, 10.1186/s12931-019-0972-7 View PDFView Record in ScopusGoogle Scholar
• A.R. Anzueto, K. Kostikas, K. Mezzi, S. Shen, M. Larbig, F. Patalano, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: Results from the FLAME study Respir Res., 19 (2018), p. 121, 10.1186/s12931-018-0830-z View PDFView Record in ScopusGoogle Scholar
• C.F. Vogelmeier, K.R. Chapman, M. Miravitlles, N. Roche, J. Vestbo, C. Thach, et al. Exacerbation heterogeneity in COPD: Subgroup analyses from the FLAME study Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 1125-1134, 10.2147/COPD.S160011 View PDFView Record in ScopusGoogle Scholar
• M.C. Chan, E.C. Tan, M.C. Yang Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 1079-1088, 10.2147/COPD.S159103 View PDFView Record in ScopusGoogle Scholar
• L. Calzetta, F. di Marco, F. Blasi, M. Cazzola, S. Centanni, C. Micheletto, et al. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis Pulm Pharmacol Ther., 59 (2019), p. 101855, 10.1016/j.pupt.2019.101855 ArticleDownload PDFView Record in ScopusGoogle Scholar
• E. Yip, S. Karimi, L.T. Pien Evaluation of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol in patients with chronic obstructive pulmonary disease J Manag Care Spec Pharm., 22 (2016), pp. 316-323 View PDFCrossRefView Record in ScopusGoogle Scholar
• D.M. Kern, J. Davis, S.A. Williams, O. Tunceli, B. Wu, S. Hollis, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: A US administrative claims database study Respir Res., 16 (2015), p. 52 View Record in ScopusGoogle Scholar
• D.S. Postma, N. Roche, G. Colice, E. Israel, R.J. Martin, W.M. van Aalderen, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD Int J Chron Obstruct Pulmon Dis., 9 (2014), pp. 1163-1186 View Record in ScopusGoogle Scholar
• J.A. Ohar, G.D. Crater, A. Emmett, T.J. Ferro, A.N. Morris, I. Raphiou, et al. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation Respir Res., 15 (2014), p. 105 View Record in ScopusGoogle Scholar
• K. Larsson, C. Janson, K. Lisspers, L. Jørgensen, G. Stratelis, G. Telg, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: The PATHOS study J Intern Med., 273 (2013), pp. 584-594 View PDFCrossRefView Record in ScopusGoogle Scholar
• V. Perrone, D. Sangiorgi, S. Buda, L. degli Esposti Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: Findings from a real-world analysis in an Italian setting Int J Chron Obstruct Pulmon Dis., 11 (2016), pp. 2749-2755 View Record in ScopusGoogle Scholar
• A.L. Aguilar-Shea, J. Bonis COPD from an everyday primary care point of view J Family Med Prim Care., 8 (2019), pp. 2644-2650, 10.4103/jfmpc.jfmpc_477_19 View PDFView Record in ScopusGoogle Scholar
• P. Solidoro, F. Patrucco, D. Bagnasco Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: A review Expert Rev Respir Med., 13 (2019), pp. 1087-1094, 10.1080/17476348.2019.1665514 View PDFView Record in ScopusGoogle Scholar
• R.H. Stanford, E.D. Parker, T.K. Reinsch, A.R. Buikema, C. Blauer-Peterson Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA Respir Med., 150 (2019), pp. 1-7, 10.1016/j.rmed.2019.01.019 ArticleDownload PDFView Record in ScopusGoogle Scholar
• K.M. Beeh, A.M. Kirsten, A.M. Tanase, A. Richard, W. Cao, B. Hederer, et al. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: Results from a Phase II randomized, double-blind 12-week study Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 3923-3936, 10.2147/COPD.S179293 View PDFView Record in ScopusGoogle Scholar
• R. Wise, P.M. Calverley, R. Dahl, D. Dusser, N. Metzdorf, A. Müller, et al. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: A post hoc analysis of the TIOSPIR trial NPJ Prim Care Respir Med., 25 (2015), p. 15067 View Record in ScopusGoogle Scholar
• A.G. Mathioudakis, V. Chatzimavridou-Grigoriadou, E. Evangelopoulou, G.A. Mathioudakis, N.M. Siafakas Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent? Pulm Pharmacol Ther., 28 (2014), pp. 91-97 ArticleDownload PDFView Record in ScopusGoogle Scholar
• S. Spila-Alegiani, F. Trotta, R. da Cas, M. Rossi, M. Venegoni, G. Traversa Comparative effectiveness of two tiotropium formulations: A retrospective cohort study COPD., 15 (2018), pp. 418-423, 10.1080/15412555.2018.1554032 View PDFView Record in ScopusGoogle Scholar
• M. Costa-Scharplatz, B. Ställberg, P. Goyal, Y. Asukai, J.B. Gruenberger, D. Price, et al. Cost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in Sweden Appl Health Econ Health Policy., 13 (2015), pp. 637-645 View PDFCrossRefView Record in ScopusGoogle Scholar
• T. Kamei, H. Nakamura, N. Nanki, Y. Minakata, K. Matsunaga, Y. Mori, Command Study Group Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: A multicentre, open-label, randomised study BMJ Open., 9 (2019), p. e024114, 10.1136/bmjopen-2018-024114 View PDFView Record in ScopusGoogle Scholar
• C.F. Vogelmeier, G.M. Asijee, K. Kupas, K.M. Beeh Tiotropium and salmeterol in COPD patients at risk of exacerbations: A post hoc analysis from POET-COPD® Adv Ther., 32 (2015), pp. 537-547 View PDFCrossRefView Record in ScopusGoogle Scholar
• M.L. Decramer, K.R. Chapman, R. Dahl, P. Frith, G. Devouassoux, C. Fritscher, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study Lancet Respir Med., 1 (2013), pp. 524-533 ArticleDownload PDFView Record in ScopusGoogle Scholar
• D. Price, Y. Asukai, J. Ananthapavan, B. Malcolm, A. Radwan, I. Keyzor A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use Appl Health Econ Health Policy., 11 (2013), pp. 259-274 View PDFCrossRefView Record in ScopusGoogle Scholar
• A. Koarai, H. Sugiura, M. Yamada, T. Ichikawa, N. Fujino, T. Kawayama, et al. Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis BMC Pulm Med, 20 (2020), p. 111, 10.1186/s12890-020-1152-8 View PDFView Record in ScopusGoogle Scholar
• F. Trudo, D.M. Kern, J.R. Davis, O. Tunceli, S. Zhou, E.L. Graham Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments Int J Chron Obstruct Pulmon Dis., 10 (2015), pp. 2055-2066 View Record in ScopusGoogle Scholar
• S.-N. Yang, H.-K. Ko, Y.-H. Hsiao, K.-C. Su, Y.L. Chang, H.-Y. Huang, et al. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment J Chin Med Assoc., 82 (2019), pp. 488-494, 10.1097/JCMA.0000000000000114 ArticleDownload PDFGoogle Scholar
• G.J. Feldman, A.R. Sousa, D.A. Lipson, L. Tombs, N. Barnes, J.H. Riley, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: A randomized study Adv Ther., 34 (2017), pp. 2518-2533, 10.1007/s12325-017-0626-4 View PDFView Record in ScopusGoogle Scholar
• M.K. Siddiqui, P. Shukla, M. Jenkins, M. Ouwens, D. Guranlioglu, P. Darken, et al. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β 2-agonist fixed-dose combinations in COPD Ther Adv Respir Dis. (2019), 10.1177/1753466619894502 View PDFGoogle Scholar
• G. Brusselle, D. Price, K. Gruffydd-Jones, M. Miravitlles, D.L. Keininger, R. Stewart, et al. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK Int J Chron Obstruct Pulmon Dis, 10 (2015), pp. 2207-2217 View Record in ScopusGoogle Scholar
• D. Singh, A. Papi, M. Corradi, I. Pavlišová, I. Montagna, C. Francisco, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial Lancet., 388 (2016), pp. 963-973 ArticleDownload PDFView Record in ScopusGoogle Scholar
• J. Vestbo, A. Papi, M. Corradi, V. Blazhko, I. Montagna, C. Francisco, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial Lancet., 389 (2017), pp. 1919-1929 ArticleDownload PDFView Record in ScopusGoogle Scholar
• A. Papi, J. Vestbo, L. Fabbri, M. Corradi, H. Prunier, G. Cohuet, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial Lancet., 391 (2018), pp. 1076-1084 ArticleDownload PDFView Record in ScopusGoogle Scholar
• P.R. Bremner, R. Birk, N. Brealey, A.S. Ismaila, C.Q. Zhu, D.A. Lipson Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study Respir Res., 19 (2018), p. 19 View Record in ScopusGoogle Scholar
• D.A. Lipson, F. Barnhart, N. Brealey, J. Brooks, G.J. Criner, N.C. Day, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD N Engl J Med., 378 (2018), pp. 1671-1680 View PDFCrossRefGoogle Scholar
• N.C. Day, S. Kumar, G. Criner, M. Dransfield, D.M.G. Halpin, M.K. Han, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: Results on cardiovascular safety from the IMPACT trial Respir Res., 21 (2020), p. 139, 10.1186/s12931-020-01398-w View PDFView Record in ScopusGoogle Scholar
• M. Kato, K. Tomii, K. Hashimoto, Y. Nezu, T. Ishii, C.E. Jones, et al. The IMPACT Study — Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: Efficacy and safety in a Japanese population Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 2849-2861, 10.2147/COPD.S226601 View PDFView Record in ScopusGoogle Scholar
• A.S. Ismaila, N. Risebrough, M. Schroeder, D. Shah, A. Martin, E.C. Goodall, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: The IMPACT trial Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 2681-2695, 10.2147/COPD.S216072 View PDFView Record in ScopusGoogle Scholar
• S. Suissa, S. dell’Aniello, P. Ernst Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in real-world clinical practice Chest., 157 (2020), pp. 846-855, 10.1016/j.chest.2019.11.007 ArticleDownload PDFView Record in ScopusGoogle Scholar
• G.T. Ferguson, N. Brown, C. Compton, T.C. Corbridge, K. Dorais, C. Fogarty, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials Respir Res., 21 (2020), p. 131, 10.1186/s12931-020-01360-w View PDFView Record in ScopusGoogle Scholar
• G.T. Ferguson, P. Darken, S. Ballal, M.K. Siddiqui, B. Singh, S. Attri, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple combinations in COPD: A systematic literature review and network meta-analysis Adv Ther., 37 (2020), pp. 2956-2975, 10.1007/s12325-020-01311-3 View PDFView Record in ScopusGoogle Scholar
• B. Alcázar-Navarrete, F. Castellano Miñán, P.J. Romero Palacios The future of triple therapy in chronic obstructive pulmonary disease Arch Bronconeumol., 54 (2018), pp. 63-64 ArticleDownload PDFView Record in ScopusGoogle Scholar
• D.L. Vetrano, A. Zucchelli, E. Bianchini, C. Cricelli, A. Piraino, M. Zibellini, et al. Triple inhaled therapy in COPD patients: Determinants of prescription in primary care Respir Med., 154 (2019), pp. 12-17 ArticleDownload PDFView Record in ScopusGoogle Scholar
• A. Papi, S. Petruzzelli, S. Vezzoli, G. Georges, L.M. Fabbri Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Eur Respir J., 53 (2019) pii: 1900147 Google Scholar
• D. Singh, L.M. Fabbri, M. Corradi, G. Georges, A. Guasconi, S. Vezzoli, et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Eur Respir J., 53 (2019), p. 1900235, 10.1183/13993003.00235-2019 View PDFView Record in ScopusGoogle Scholar